RT Journal
A1 Kuehn BM
T1 LEukotriene inhibitor warning
JF JAMA
JO JAMA
YR 2009
FD July 22
VO 302
IS 4
SP 375
OP 375
DO 10.1001/jama.2009.1048
UL http://dx.doi.org/10.1001/jama.2009.1048
AB 
Since 2007, Merck & Co, Inc, the manufacturer of montelukast, voluntarily added tremor, depression, suicidality, and anxiousness to the list on the drug's label of postmarketing adverse events that have been reported in patients taking the drug. Now, the agency wants a stronger caution on the label of montelukast regarding psychiatric adverse events, as well as similar changes to the labels of asthma drugs zafirlukast and zileuton, which have a similar method of action.